GLPG (Galapagos NV) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Debt-to-Asset?

Galapagos NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $3.6 Mil. Galapagos NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $8.6 Mil. Galapagos NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $4,330.6 Mil. Galapagos NV's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Galapagos NV Debt-to-Asset Historical Data

The historical data trend for Galapagos NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Debt-to-Asset Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.01

Galapagos NV Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Galapagos NV's Debt-to-Asset

For the Biotechnology subindustry, Galapagos NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Galapagos NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Galapagos NV's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.643	+	8.631)	/	4330.596
	=	0.00

Galapagos NV's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.643	+	8.631)	/	4330.596
	=	0.00

Galapagos NV (NAS:GLPG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Galapagos NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXEA:Germany GXE:Germany GXEA:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.